Fresenius Taps China’s WuXi to Expand Biosimilar Drug Portfolio

Fresenius SE announced a partnership with WuXi Biologics to develop biosimilar drug candidates. The candidates are expected to reach market within the next decade. The partnership could increase Fresenius's current biosimilar portfolio by more than double, according to the announcement.

• Bloomberg — Fresenius Taps China’s WuXi to Expand Biosimilar Drug Portfolio

Next story